Weight-Loss Injections Under Scrutiny: New Genetic Study Launched After Pancreas Side Effect Reports

Photo Disclosure Internet

They’ve been hailed as revolutionary treatments in the fight against obesity and type 2 diabetes. But now, the most popular weight-loss injections—Ozempic, Wegovy, and Mounjaro—are facing renewed scrutiny as growing numbers of users report serious pancreatic side effects. In response, UK health authorities have launched a pioneering genetic study to uncover why some patients are more vulnerable than others.

A Wake-Up Call from the Data

Since their widespread adoption, GLP‑1 receptor agonists—medications that mimic a hormone involved in insulin production and appetite regulation—have been linked to a wide range of side effects, most commonly nausea, vomiting, and diarrhea. But a more alarming trend has emerged: an increasing number of suspected cases of acute and chronic pancreatitis.

According to data released by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA):

• 181 reports of pancreatic inflammation were linked to tirzepatide (sold as Mounjaro), including five deaths.

• 113 cases were tied to semaglutide (Ozempic/Wegovy), including one death.

• Other drugs in the same class, such as liraglutide, exenatide, and dulaglutide, were also implicated.

While these figures do not confirm a causal link, they were enough to prompt action.

A Genetic Approach to Patient Safety

To investigate the root of these reactions, the MHRA has partnered with Genomics England to expand the Yellow Card Biobank—a program that combines adverse event reports with genomic data. The goal is simple but urgent: identify whether specific genetic markers may predispose individuals to serious complications from these drugs.

According to Dr. Alison Cave, the MHRA’s Chief Safety Officer, “Up to one in three side effects could potentially be prevented if we understood the patient’s genetic makeup. This study brings us closer to personalized, safer prescribing.”

Patients who’ve been hospitalized with pancreatitis after using GLP‑1 drugs are now being invited to participate in the study. Their genetic profiles could help identify patterns that explain the body’s adverse reaction to these therapies.

Balancing Risk and Benefit

GLP‑1 drugs have dramatically changed obesity treatment, offering not only weight loss but also improved cardiovascular outcomes and better diabetes control. However, growing concerns about their long-term effects are becoming harder to ignore.

Recent studies suggest these drugs may double the risk of pancreatitis, and have been associated with gastroparesis(slowed digestion), intestinal blockages, and other serious gastrointestinal problems. While rare, such complications can be life-threatening and life-altering.

Interestingly, some data also indicate that semaglutide may lower the risk of pancreatitis in diabetic populations when compared to older diabetes medications. This adds complexity to the picture—and reinforces the need to understand which patients benefit and which might be at risk.

From Lawsuits to Labels

Pharmaceutical giants Novo Nordisk and Eli Lilly, who manufacture the best-selling drugs in this class, have already updated their labels to include pancreatitis warnings. Both companies continue to monitor safety data and cooperate with regulators, but the growing number of lawsuits and anecdotal accounts have cast a shadow on these previously untouchable treatments.

In the US and UK alike, patients have come forward with stories of unexplained abdominal pain, hospitalizations, and long-term digestive issues. “I lost 20 kilos,” said one former Wegovy user, “but I nearly lost my pancreas too.”

Toward a Future of Safer Prescriptions

The MHRA’s genetic initiative could be a turning point—not just for GLP‑1 therapies, but for how modern medicine approaches side effects in general. By mapping how genetics influence drug responses, the agency hopes to pave the way for precision prescribing, where risk is known before the first injection is ever given.

Until then, doctors are urged to assess patients thoroughly and educate them on early signs of pancreatitis—persistent abdominal pain, vomiting, and fever—before continuing or renewing prescriptions.